Article
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Oct 2009
Ambrosone Christine B, Barlow William E, Reynolds Wanda, Livingston Robert B, Yeh I-Tien, Choi Ji-Yeob, Davis Warren, Rae James M, Tang Li, Hutchins Laura R, Ravdin Peter M, Martino Silvana, Osborne C Kent, Lyss Alan P, Hayes Daniel F, Albain Kathy S
Abstract excerpt
PURPOSE: Myeloperoxidase (MPO) generates reactive oxygen species and also activates xenobiotics. In a rigorous clinical trial (Southwest Oncology Group SWOG-8897), we examined relationships between genotypes and disease-free survival (DFS) among women treated for breast cancer, as well as those who did not receive adjuvant chemotherapy. PATIENTS AND METHODS: Patients were assigned to risk groups according to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
